These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 39298484)

  • 1. In vivo CRISPR screens identify
    Feng X; Yang C; Huang Y; Su D; Wang C; Wilson LL; Yin L; Tang M; Li S; Chen Z; Zhu D; Wang S; Zhang S; Zhang J; Zhang H; Nie L; Huang M; Park JI; Hart T; Jiang D; Jiang K; Chen J
    Proc Natl Acad Sci U S A; 2024 Sep; 121(39):e2406325121. PubMed ID: 39298484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo multidimensional CRISPR screens identify
    Ji P; Gong Y; Jin ML; Wu HL; Guo LW; Pei YC; Chai WJ; Jiang YZ; Liu Y; Ma XY; Di GH; Hu X; Shao ZM
    Sci Adv; 2022 Jul; 8(26):eabl8247. PubMed ID: 35767614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target.
    Wang X; Tokheim C; Gu SS; Wang B; Tang Q; Li Y; Traugh N; Zeng Z; Zhang Y; Li Z; Zhang B; Fu J; Xiao T; Li W; Meyer CA; Chu J; Jiang P; Cejas P; Lim K; Long H; Brown M; Liu XS
    Cell; 2021 Oct; 184(21):5357-5374.e22. PubMed ID: 34582788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens.
    Yim S; Hwang W; Han N; Lee D
    Front Immunol; 2022; 13():884561. PubMed ID: 35651625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
    Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
    Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.
    Dong MB; Wang G; Chow RD; Ye L; Zhu L; Dai X; Park JJ; Kim HR; Errami Y; Guzman CD; Zhou X; Chen KY; Renauer PA; Du Y; Shen J; Lam SZ; Zhou JJ; Lannin DR; Herbst RS; Chen S
    Cell; 2019 Aug; 178(5):1189-1204.e23. PubMed ID: 31442407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A CRISPR Platform for Targeted In Vivo Screens.
    Maranda V; Zhang Y; Vizeacoumar FS; Freywald A; Vizeacoumar FJ
    Methods Mol Biol; 2023; 2614():397-409. PubMed ID: 36587138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy.
    Dai M; Yan G; Wang N; Daliah G; Edick AM; Poulet S; Boudreault J; Ali S; Burgos SA; Lebrun JJ
    Nat Commun; 2021 May; 12(1):3055. PubMed ID: 34031411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
    Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
    Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
    Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
    Hou J; Wang Y; Shi L; Chen Y; Xu C; Saeedi A; Pan K; Bohat R; Egan NA; McKenzie JA; Mbofung RM; Williams LJ; Yang Z; Sun M; Liang X; Rodon Ahnert J; Varadarajan N; Yee C; Chen Y; Hwu P; Peng W
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor immune evasion: insights from CRISPR screens and future directions.
    Djajawi TM; Wichmann J; Vervoort SJ; Kearney CJ
    FEBS J; 2024 Apr; 291(7):1386-1399. PubMed ID: 37971319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy.
    Potts MA; McDonald JA; Sutherland KD; Herold MJ
    Eur J Immunol; 2020 Dec; 50(12):1871-1884. PubMed ID: 33202035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of metabolic reprogramming in immune escape of triple-negative breast cancer.
    Bao R; Qu H; Li B; Cheng K; Miao Y; Wang J
    Front Immunol; 2024; 15():1424237. PubMed ID: 39192979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer.
    Kudelova E; Smolar M; Holubekova V; Hornakova A; Dvorska D; Lucansky V; Koklesova L; Kudela E; Kubatka P
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
    Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
    Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas genome editing in triple negative breast cancer: Current situation and future directions.
    Fu L; Li Z; Ren Y; Yu H; Liu B; Qiu Y
    Biochem Pharmacol; 2023 Mar; 209():115449. PubMed ID: 36754153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An In Vivo CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression.
    Lu XX; Yang WX; Pei YC; Luo H; Li XG; Wang YJ; Zhang GL; Ling H; Shao ZM; Hu X
    Cancer Res; 2023 Jun; 83(12):2000-2015. PubMed ID: 37057875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.